Zimmer Biomet (NYSE: ZBH) + is voluntarily phasing out its CPT hip system amid a voluntary recall. 

The FDA today issued an alert to people with the hip system, their caregivers, and healthcare providers that warns of increased risk of thigh bone fracture after surgery (postoperative periprosthetic femoral fracture) with the use of ZB’s CPT hip system femoral stem 12/14 neck tape.

Zimmer Biomet voluntarily recalled the hip system on July 2 to update use instructions due to the increased thigh bone fracture risk. It also said it planned to phase out sales of the CPT hip system by December 2024. The company informed health providers that they should consider using alternative hip systems when possible.

In a statement shared by a spokesperson with MassDevice, ZB said:

“Zimmer Biomet is committed to the highest standards of patient safety, quality and integrity. The CPT Hip System has been on the market for more than 20 years, with a high survivorship rate of 96.4% at 10 years. We are now supporting customers to transition to alternative Zimmer Biomet brands as we voluntarily phase out the CPT hip system femoral stem 12/14 neck taper in 2024.”

The FDA has more details in its safety communication.